LRP5 and osteoporosis-pseudoglioma syndrome: Specifically, loss of function mutations in the Wnt-co receptor LRP5, as seen in osteoporosis pseudoglioma syndrome, result in a dramatic loss in bone mass [26], while gain of function mutations give rise to extremely high BMD (5 SD above normal) [27].